NCT01824342View on ClinicalTrials.gov

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Castrate-resistant Prostate Cancer
Interventions
BIOLOGICAL

Denosumab

Administered by subcutaneous injection

Trial Locations (9)

500 05

Research Site, Hradec Králové

393 38

Research Site, Pelhřimov

128 08

Research Site, Prague

160 00

Research Site, Prague

390 03

Research Site, Tábor

NE7 7DN

Research Site, Newcastle

HA6 2RN

Research Site, Northwood

S10 2SJ

Research Site, Sheffield

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01824342 - Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter